Unity Biotechnology (UBX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	9.79 mm	9.79 mm	9.79 mm	9.79 mm	9.79 mm	9.79 mm
Cash burn (monthly)	(no burn)	(no burn)	2.20 mm	2.40 mm	1.73 mm	1.88 mm
Cash used (since last report)	n/a	n/a	11.18 mm	12.22 mm	8.80 mm	9.54 mm
Cash remaining	n/a	n/a	-1.39 mm	-2.43 mm	997.58 k	250.99 k
Runway (months of cash)	n/a	n/a	-0.6	-1.0	0.6	0.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

UBX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	43	43	–
Opened positions	7	6	+16.7%
Closed positions	7	7	–
Increased positions	4	7	-42.9%
Reduced positions	9	11	-18.2%

13F shares	Current	Prev Q	Change
Total value	5.12 bn	4.69 bn	+9.1%
Total shares	19.24 mm	19.23 mm	+0.1%
Total puts	16.20 k	600.00	+2600.0%
Total calls	59.00 k	41.40 k	+42.5%
Total put/call ratio	0.3	0.0	+1794.6%

Largest owners	Shares	Value	Change
Arch Venture Fund VII	10.05 mm	$14.67 mm	0.0%
Venrock Associates VII	2.68 mm	$0.00	0.0%
Mayo Foundation For Medical Education & Research	1.57 mm	$25.56 mm	0.0%
WuXi PharmTech Healthcare Fund I	1.48 mm	$24.03 mm	0.0%
Arch Venture	1.00 mm	$1.48 bn	0.0%
Alyeska Investment	920.01 k	$1.35 bn	0.0%
Vanguard	590.77 k	$868.43 mm	0.0%
Geode Capital Management	163.24 k	$240.02 mm	+9.5%
Mayo Clinic	124.08 k	$182.40 mm	0.0%
Renaissance Technologies	93.67 k	$137.70 mm	+45.0%

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	0.00	-88.39 k	EXIT
BlackRock	81.17 k	+81.17 k	NEW
Ballentine Partners	57.05 k	+57.05 k	NEW
WFC Wells Fargo & Company	61.00	-43.34 k	-99.9%
Renaissance Technologies	93.67 k	+29.09 k	+45.0%
Susquehanna International	0.00	-17.84 k	EXIT
Geode Capital Management	163.24 k	+14.20 k	+9.5%
Millennium Management	0.00	-10.48 k	EXIT
MS Morgan Stanley	44.69 k	-8.52 k	-16.0%
Ubs Oconnor	79.35 k	+7.37 k	+10.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

UBX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
4 Feb 25	Alexander Hieu Nguyen	Common Stock, $0.0001 par value	Sell	Dispose S	No	Yes	2.23	164	365.72	24,559
4 Feb 25	Sullivan Lynne Marie	Common Stock, $0.0001 par value	Sell	Dispose S	No	Yes	2.23	153	341.19	55,772
4 Feb 25	Anirvan Ghosh	Common Stock, $0.0001 par value	Sell	Dispose S	No	Yes	2.23	642	1.43 k	75,251
22 Jan 25	Anirvan Ghosh	Stock Option Common Stock	Grant	Acquire A	No	No	2.09	450,000	940.50 k	450,000
22 Jan 25	Alexander Hieu Nguyen	Stock Option Common Stock	Grant	Acquire A	No	No	2.09	150,000	313.50 k	150,000

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

12 Health Care Stocks Moving In Monday's Pre-Market Session

27 Jan 25

12 Health Care Stocks Moving In Monday's Pre-Market Session

27 Jan 25

Chardan Capital Initiates Coverage On Unity Biotechnology with Buy Rating, Announces Price Target of $6

10 Jan 25

Chardan Capital analyst Daniil Gataulin initiates coverage on Unity Biotechnology (NASDAQ:UBX) with a Buy rating and announces Price Target of $6.

Press releases

From Benzinga Pro

UNITY Biotechnology Reports Granting of New Employment Inducement Award

7 Jan 25

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. ("UNITY") (NASDAQ:UBX), a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today